Advanced

Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.

Sandén, Emma LU ; Dyberg, Cecilia; Krona, Cecilia; Visse, Edward LU ; Carén, Helena; Northcott, Paul A; Kool, Marcel; Ståhl, Nils LU ; Persson, Annette LU and Englund, Elisabet LU , et al. (2015) In Journal of Neurooncology 123(1). p.1-13
Abstract
The CD24 glycoprotein is a mediator of neuronal proliferation, differentiation and immune suppression in the normal CNS, and a proposed cancer biomarker in multiple peripheral tumor types. We performed a comparative analysis of CD24 gene expression in a large cohort of pediatric and adult brain tumors (n = 813), and further characterized protein expression in tissue sections (n = 39), primary brain tumor cultures (n = 12) and a novel orthotopic group 3 medulloblastoma xenograft model. Increased CD24 gene expression was demonstrated in ependymomas, medulloblastomas, anaplastic astrocytomas and glioblastomas, although medulloblastomas displayed higher expression than all other tumor entities. Preferential expression of CD24 in... (More)
The CD24 glycoprotein is a mediator of neuronal proliferation, differentiation and immune suppression in the normal CNS, and a proposed cancer biomarker in multiple peripheral tumor types. We performed a comparative analysis of CD24 gene expression in a large cohort of pediatric and adult brain tumors (n = 813), and further characterized protein expression in tissue sections (n = 39), primary brain tumor cultures (n = 12) and a novel orthotopic group 3 medulloblastoma xenograft model. Increased CD24 gene expression was demonstrated in ependymomas, medulloblastomas, anaplastic astrocytomas and glioblastomas, although medulloblastomas displayed higher expression than all other tumor entities. Preferential expression of CD24 in medulloblastomas was confirmed at protein level by immunostaining and computerized image analysis of cryosections. Morphologies and immunophenotyping of CD24(+) cells in tissue sections tentatively suggested disparate functions in different tumor subsets. Notably, protein staining of medulloblastoma cells was associated with prominent cytoplasmic and membranous granules, enabling rapid and robust identification of medulloblastoma cells in clinical tissue samples, as well as in experimental model systems. In conclusion, our results implicate CD24 as a clinically and experimentally useful medulloblastoma immunomarker. Although our results encourage further functional studies of CD24 as a potential molecular target in subsets of brain tumors, the promiscuous expression of CD24 in vivo highlights the importance of specificity in the future design of such targeted treatment. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Neurooncology
volume
123
issue
1
pages
1 - 13
publisher
Springer
external identifiers
  • pmid:25820321
  • wos:000354893700001
  • scopus:84929834477
ISSN
1573-7373
DOI
10.1007/s11060-015-1758-5
language
English
LU publication?
yes
id
b2b2afbd-9a32-4891-bebd-6d86a7aeae7f (old id 5257322)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25820321?dopt=Abstract
date added to LUP
2015-04-04 16:31:22
date last changed
2017-05-14 03:13:44
@article{b2b2afbd-9a32-4891-bebd-6d86a7aeae7f,
  abstract     = {The CD24 glycoprotein is a mediator of neuronal proliferation, differentiation and immune suppression in the normal CNS, and a proposed cancer biomarker in multiple peripheral tumor types. We performed a comparative analysis of CD24 gene expression in a large cohort of pediatric and adult brain tumors (n = 813), and further characterized protein expression in tissue sections (n = 39), primary brain tumor cultures (n = 12) and a novel orthotopic group 3 medulloblastoma xenograft model. Increased CD24 gene expression was demonstrated in ependymomas, medulloblastomas, anaplastic astrocytomas and glioblastomas, although medulloblastomas displayed higher expression than all other tumor entities. Preferential expression of CD24 in medulloblastomas was confirmed at protein level by immunostaining and computerized image analysis of cryosections. Morphologies and immunophenotyping of CD24(+) cells in tissue sections tentatively suggested disparate functions in different tumor subsets. Notably, protein staining of medulloblastoma cells was associated with prominent cytoplasmic and membranous granules, enabling rapid and robust identification of medulloblastoma cells in clinical tissue samples, as well as in experimental model systems. In conclusion, our results implicate CD24 as a clinically and experimentally useful medulloblastoma immunomarker. Although our results encourage further functional studies of CD24 as a potential molecular target in subsets of brain tumors, the promiscuous expression of CD24 in vivo highlights the importance of specificity in the future design of such targeted treatment.},
  author       = {Sandén, Emma and Dyberg, Cecilia and Krona, Cecilia and Visse, Edward and Carén, Helena and Northcott, Paul A and Kool, Marcel and Ståhl, Nils and Persson, Annette and Englund, Elisabet and Johnsen, John I and Siesjö, Peter and Darabi, Anna},
  issn         = {1573-7373},
  language     = {eng},
  number       = {1},
  pages        = {1--13},
  publisher    = {Springer},
  series       = {Journal of Neurooncology},
  title        = {Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.},
  url          = {http://dx.doi.org/10.1007/s11060-015-1758-5},
  volume       = {123},
  year         = {2015},
}